Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Posts 14-Percent Rise in Revenues, Increased Earnings in Q1

NEW YORK, May 6 (GenomeWeb News) - Bio-Rad Laboratories yesterday reported a 14-percent increase in revenues and a jump in earnings for the first quarter of 2005.

 

The company recorded $299.2 million in revenues for the quarter, up from $262.7 million during the same period a year ago. Bio-Rad's life science segment accounted for $144.1 million of total revenues, an increase of 18.5 percent year-over-year.

 

Several product lines, including amplification reagents, process chromatography media, and the Bio-Plex protein assay system, contributed to the growth of this segment, while real time PCR instruments faced competition, and prices for BSE tests "eroded," according to the company.

 

Research and development costs went up slightly, to $26.8 million, from $24.3 million during last year's first quarter.

 

Net income totaled $33.5 million, or $1.26 per share, up from $22 million, or $.83 per share, during the first quarter of 2004. This includes a $4 million gain related to the sale of the company's confocal microscopy business.

 

As of March 31, Bio-Rad had $318 million in cash and cash equivalents and $65.9 million in short-term investments.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.